Quick Heal Technologies Ltd Q3 FY25 Results & Concall Highlights: Revenue ₹7.2 Cr
Published 15 Jul 2026 | IT - Software | Market Cap: ₹830 Cr
Quick Heal has a healthy pipeline and growing order book, indicating confidence in FY’26 outlook. Q3 FY’25 showed a muted performance with a 4% QoQ revenue decline and 14% YoY decline due to headwinds in consumer and government verticals.
From Quick Heal Technologies Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹143
Market Cap
₹830 Cr
How does Quick Heal Technologies Ltd rank in IT - Software?
Compare Quick Heal Technologies Ltd against every IT - Software company this quarter on revenue, margins and earnings-call signals.
Quick Heal Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹49 Cr, net profit ₹-20 Cr.
Full financials →📊 Revenue & Sales Performance
- →Quick Heal has a healthy pipeline and growing order book, indicating confidence in FY’26 outlook.
- →Enterprise order book has reached material size (₹7.2 crores) with deferred revenue building up (₹10 crores), providing revenue visibility and predictability.
- →New product launches like AntiFraud.AI, Seqrite Malware Analysis, and Seqrite Threat Intelligence target emerging enterprise cybersecurity needs, expected to drive future sales.
- →DPDP and cybersecurity regulatory compliance expected to boost sales across data privacy and cybersecurity products; average deal size for mid-market ₹75 lakhs to ₹3 crores.
- →Consumer segment industry facing de-growth, but Quick Heal plans a flattish revenue trend and increased marketing efforts, e.g. for AntiFraud product.
- →Strategic hiring and academy business aim to build capacity and drive market expansion.
- →Overall, focus on innovation, strategic partnerships, and new product pipeline expected to underpin growth and value creation.
📈 Profitability & Margins
- →Q3 FY’25 showed a muted performance with a 4% QoQ revenue decline and 14% YoY decline due to headwinds in consumer and government verticals.
- →Company confident in FY’26 outlook, backed by a healthy enterprise pipeline and growing order book and deferred revenue, providing better predictability.
- →Investments in Horizon 3 product launches (e.g., AntiFraud.AI) may pressure short-term profitability but aim to drive long-term growth.
- →EBITDA was negative INR 3.8 crore in Q3 FY’25; however, 9-month EBITDA stood at INR 1.9 crore.
- →PAT for Q3 FY’25 was INR 0.1 crore, indicating near breakeven.
- →Expect growth from expanding enterprise business, strategic partnerships, and new product launches like DPDP compliance, threat intelligence, and malware analysis.
- →Order book and deferred revenue are building, signaling more stable and predictable future revenues.
- →Emphasis on innovation and market expansion supports a transformational pivot expected to yield earnings growth over time.
🏗️ Capital Expenditure Plans
- →The company has made capital expenditure on a Tier 3 data center at their Pune office, involving a significant CAPEX spend.
- →Despite this investment, the cash balance remains steady at around Rs. 190 crores.
- →There are no specific future capex plans detailed in the call, but the company mentions continuous investments in new product launches like AntiFraud and Horizon 3 categories.
- →Strategic investments include partnerships and MOUs with institutions such as the Banking Institute of Rural Development Lucknow, NFSU, and IIM Nagpur to foster collaborative research in cybersecurity.
- →The focus on R&D and innovation indicates ongoing strategic investments in new product development and market expansion.
💰 Fundraising & Capital Structure
- →There is no mention of any current or planned new fundraising through debt or equity in the Q3 FY’25 earnings call transcript.
- →The company states it is "cash-rich" with a cash and investment balance of ₹190 crores as of Q3 FY’25.
- →Investments have been internally funded, for example, CAPEX spent on a Tier 3 data center in Pune.
- →The focus appears to be on organic growth, strategic hiring, product launches, and expanding order book without external fundraising.
- →No public disclosures or comments about raising new capital through debt or equity were made during the call.
📋 Order Book & Pipeline
- →Quick Heal's enterprise order book as of Q3 FY'25 stands at ₹7.2 crores, a significant increase from ₹35 lakhs at the end of Q2.
- →Deferred revenue has grown by around ₹8 crores over the past 9 months, totaling ₹10 crores at the end of Q3 FY'25.
- →The order book primarily consists of confirmed purchase orders/contracts, mainly from enterprise customers, domestic and international.
- →These orders typically span over contract tenures of 1 to 3 years.
- →The order book and deferred revenue are additional to the current quarterly enterprise revenue run rate of around ₹30 crores.
- →This is the first time Quick Heal is reporting a material enterprise order book, reflecting higher business predictability.
- →The order book and deferred revenue provide comfort on future revenue visibility beyond the existing run rate.
Key Metrics
Frequently Asked Questions
What were Quick Heal Technologies Ltd Q3 FY25 results?
Quick Heal has a healthy pipeline and growing order book, indicating confidence in FY’26 outlook. Q3 FY’25 showed a muted performance with a 4% QoQ revenue decline and 14% YoY decline due to headwinds in consumer and government verticals.
What is Quick Heal Technologies Ltd share price analysis?
Quick Heal Technologies Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹830 Cr. Investors should review the full earnings analysis for detailed insights.
Is Quick Heal Technologies Ltd planning capital expenditure?
The company has made capital expenditure on a Tier 3 data center at their Pune office, involving a significant CAPEX spend. - Despite this investment, the cash balance remains steady at around Rs.
Keep Quick Heal Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.